The drug, Calquence, is used to combat Mantle cell lymphoma after a prior treatment has failed. It is a kinase inhibibitor that blocks an enzyme the cancer needs to multiply and spread.
“Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence. “For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies.”
The drug was approved using the FDA’s accelerated approval pathway.
More articles on supply chain:
FDA hires Mylan exec as senior communications adviser
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
Analysis: Biosimilar drugs could cut US healthcare spending by $54B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.